Court blocks mailing prescriptions of abortion pill mifepristone

Key Points:

• A federal appeals court ruled unanimously to block the mailing of mifepristone prescriptions, requiring the abortion pill to be distributed only in person at clinics, overruling FDA regulations and impacting abortion access nationwide.
• The ruling supports Louisiana's argument that mailed mifepristone undermines the state's abortion ban and challenges the FDA's authority, marking a significant shift in abortion policy since the overturning of Roe v. Wade.
• Mifepristone, approved in 2000 and involved in most early abortions, has seen increased telehealth prescriptions, especially in states with abortion bans, prompting legislative and legal challenges from abortion opponents.
• The court's decision departs from typical deference to FDA scientific judgments, citing ongoing safety reviews and concerns about rare side effects, despite decades of data supporting the pill's safety and prior relaxed distribution rules during COVID-19.
• The ruling is expected to be appealed to the Supreme Court, with manufacturers seeking emergency relief, while abortion rights advocates warn it will restrict access to abortion and miscarriage care, disproportionately affecting vulnerable populations.